Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Evaluation of Canonical siRNA and Dicer Substrate RNA for Inhibition of Hepatitis C Virus Genome Replication - A Comparative Study

Full text
Carneiro, Bruno [1, 2] ; Silva Braga, Ana Claudia [1] ; Batista, Mariana Nogueira [1] ; Harris, Mark [2] ; Rahal, Paula [1]
Total Authors: 5
[1] Sao Paulo State Univ, IBILCE, Genom Study Lab, Sao Jose Do Rio Preto, SP - Brazil
[2] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire - England
Total Affiliations: 2
Document type: Journal article
Source: PLoS One; v. 10, n. 2 FEB 23 2015.
Web of Science Citations: 5

Hepatitis C virus (HCV) frequently establishes persistent infections in the liver, leading to the development of chronic hepatitis and, potentially, to liver cirrhosis and hepatocellular carcinoma at later stages. The objective of this study was to test the ability of five Dicer substrate siRNAs (DsiRNA) to inhibit HCV replication and to compare these molecules to canonical 21 nt siRNA. DsiRNA molecules were designed to target five distinct regions of the HCV genome -the 5' UTR and the coding regions for NS3, NS4B, NS5A or NS5B. These molecules were transfected into Huh7.5 cells that stably harboured an HCV subgenomic replicon expressing a firefly luciferase/neoR reporter (SGR-Feo-JFH-1) and were also tested on HCVcc-infected cells. All of the DsiRNAs inhibited HCV replication in both the subgenomic system and HCVcc-infected cells. When DsiRNAs were transfected prior to infection with HCVcc, the inhibition levels reached 99.5%. When directly compared, canonical siRNA and DsiRNA exhibited similar potency of virus inhibition. Furthermore, both types of molecules exhibited similar dynamics of inhibition and frequencies of resistant mutants after 21 days of treatment. Thus, DsiRNA molecules are as potent as 21 nt siRNAs for the inhibition of HCV replication and may provide future approaches for HCV therapy if the emergence of resistant mutants can be addressed. (AU)

FAPESP's process: 09/08534-9 - Analysis of RNA interference (RNAi) on in vitro replication of Hepatitis C virus.
Grantee:Bruno Moreira Carneiro
Support type: Scholarships in Brazil - Doctorate